• +1-646-491-9876
    • +91-20-67278686

    Search

    Myasthenia Gravis Pipeline Review H2 2017

    Myasthenia Gravis Pipeline Review H2 2017

    • Report Code ID: RW0001884158
    • Category Pharmaceuticals
    • No. of Pages 122
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Myasthenia Gravis - Pipeline Review, H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Myasthenia Gravis - Pipeline Review, H2 2017, provides an overview of the Myasthenia Gravis (Immunology) pipeline landscape.

    Myasthenia gravis is autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any of the muscles under voluntary control. Symptoms include drooping of one or both eyelids, diplopia and difficulty swallowing, chewing and speaking. Treatment includes immunosuppressants, corticosteroids and surgery.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Myasthenia Gravis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Myasthenia Gravis (Immunology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Myasthenia Gravis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Myasthenia Gravis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 5, 4, 11 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

    Myasthenia Gravis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Myasthenia Gravis (Immunology) .
    - The pipeline guide reviews pipeline therapeutics for Myasthenia Gravis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Myasthenia Gravis (Immunology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Myasthenia Gravis (Immunology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Myasthenia Gravis (Immunology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Myasthenia Gravis (Immunology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Myasthenia Gravis (Immunology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 4
    List of Figures 5
    Introduction 6
    Publisher Report Coverage 6
    Myasthenia Gravis - Overview 7
    Myasthenia Gravis - Therapeutics Development 8
    Pipeline Overview 8
    Pipeline by Companies 9
    Pipeline by Universities/Institutes 12
    Products under Development by Companies 13
    Products under Development by Universities/Institutes 15
    Myasthenia Gravis - Therapeutics Assessment 16
    Assessment by Target 16
    Assessment by Mechanism of Action 18
    Assessment by Route of Administration 20
    Assessment by Molecule Type 22
    Myasthenia Gravis - Companies Involved in Therapeutics Development 24
    Achillion Pharmaceuticals Inc 24
    Akari Therapeutics Plc 24
    Alexion Pharmaceuticals Inc 25
    Alpha Cancer Technologies Inc 25
    Apellis Pharmaceuticals Inc 26
    arGEN-X BV 26
    BioMarin Pharmaceutical Inc 27
    Bristol-Myers Squibb Company 27
    CuraVac Inc 28
    GlaxoSmithKline Plc 28
    Grifols SA 29
    HanAll Biopharma Co Ltd 29
    Millennium Pharmaceuticals Inc 30
    Neurotune AG 30
    Novartis AG 31
    Pfizer Inc 31
    Ra Pharmaceuticals Inc 32
    Regenesance BV 32
    Shire Plc 33
    Toleranzia AB 33
    UCB SA 34
    Myasthenia Gravis - Drug Profiles 35
    abatacept - Drug Profile 35
    ACT-101 - Drug Profile 43
    amifampridine phosphate - Drug Profile 45
    APL-2 - Drug Profile 51
    belimumab - Drug Profile 54
    bortezomib - Drug Profile 61
    CFZ-533 - Drug Profile 69
    CVMG-01 - Drug Profile 71
    eculizumab - Drug Profile 73
    efgartigimod alfa - Drug Profile 83
    GL-2045 - Drug Profile 86
    HL-161 - Drug Profile 88
    immune globulin (human) - Drug Profile 89
    methotrexate - Drug Profile 91
    NT-1654 - Drug Profile 92
    RA-101495 - Drug Profile 93
    Recombinant Protein for Myasthenia Gravis - Drug Profile 96
    Recombinant Protein to Target CHRNA1 for Myasthenia Gravis - Drug Profile 97
    Recombinant Proteins to Inhibit Complement C5 for Myasthenia Gravis - Drug Profile 98
    Regenemab - Drug Profile 99
    rozanolixizumab - Drug Profile 100
    SM-201 - Drug Profile 101
    Small Molecules to Inhibit Complement Factor D for Myasthenia Gravis - Drug Profile 102
    Synthetic Peptide to Inhibit Complement C5 for Autoimmune Disorders, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile 103
    TK-21 - Drug Profile 104
    Vaccine for Myasthenia Gravis - Drug Profile 105
    Vaccine for Myasthenia Gravis - Drug Profile 106
    Myasthenia Gravis - Dormant Projects 107
    Myasthenia Gravis - Discontinued Products 108
    Myasthenia Gravis - Product Development Milestones 109
    Featured News & Press Releases 109
    Appendix 119
    Methodology 119
    Coverage 119
    Secondary Research 119
    Primary Research 119
    Expert Panel Validation 119
    Contact Us 119
    Disclaimer 120

    List of Tables

    Number of Products under Development for Myasthenia Gravis, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..1) , H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Products under Development by Companies, H2 2017
    Products under Development by Companies, H2 2017 (Contd..1) , H2 2017
    Products under Development by Universities/Institutes, H2 2017
    Number of Products by Stage and Target, H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    Myasthenia Gravis - Pipeline by Achillion Pharmaceuticals Inc, H2 2017
    Myasthenia Gravis - Pipeline by Akari Therapeutics Plc, H2 2017
    Myasthenia Gravis - Pipeline by Alexion Pharmaceuticals Inc, H2 2017
    Myasthenia Gravis - Pipeline by Alpha Cancer Technologies Inc, H2 2017
    Myasthenia Gravis - Pipeline by Apellis Pharmaceuticals Inc, H2 2017
    Myasthenia Gravis - Pipeline by arGEN-X BV, H2 2017
    Myasthenia Gravis - Pipeline by BioMarin Pharmaceutical Inc, H2 2017
    Myasthenia Gravis - Pipeline by Bristol-Myers Squibb Company, H2 2017
    Myasthenia Gravis - Pipeline by CuraVac Inc, H2 2017
    Myasthenia Gravis - Pipeline by GlaxoSmithKline Plc, H2 2017
    Myasthenia Gravis - Pipeline by Grifols SA, H2 2017
    Myasthenia Gravis - Pipeline by HanAll Biopharma Co Ltd, H2 2017
    Myasthenia Gravis - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
    Myasthenia Gravis - Pipeline by Neurotune AG, H2 2017
    Myasthenia Gravis - Pipeline by Novartis AG, H2 2017
    Myasthenia Gravis - Pipeline by Pfizer Inc, H2 2017
    Myasthenia Gravis - Pipeline by Ra Pharmaceuticals Inc, H2 2017
    Myasthenia Gravis - Pipeline by Regenesance BV, H2 2017
    Myasthenia Gravis - Pipeline by Shire Plc, H2 2017
    Myasthenia Gravis - Pipeline by Toleranzia AB, H2 2017
    Myasthenia Gravis - Pipeline by UCB SA, H2 2017
    Myasthenia Gravis - Dormant Projects, H2 2017
    Myasthenia Gravis - Discontinued Products, H2 2017

    List of Figures

    Number of Products under Development for Myasthenia Gravis, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Number of Products by Top 10 Targets, H2 2017
    Number of Products by Stage and Top 10 Targets, H2 2017
    Number of Products by Top 10 Mechanism of Actions, H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
    Number of Products by Routes of Administration, H2 2017
    Number of Products by Stage and Routes of Administration, H2 2017
    Number of Products by Molecule Types, H2 2017
    Number of Products by Stage and Molecule Types, H2 2017
    Achillion Pharmaceuticals Inc
    Akari Therapeutics Plc
    Alexion Pharmaceuticals Inc
    Alpha Cancer Technologies Inc
    Apellis Pharmaceuticals Inc
    arGEN-X BV
    BioMarin Pharmaceutical Inc
    Bristol-Myers Squibb Company
    CuraVac Inc
    GlaxoSmithKline Plc
    Grifols SA
    HanAll Biopharma Co Ltd
    Millennium Pharmaceuticals Inc
    Neurotune AG
    Novartis AG
    Pfizer Inc
    Ra Pharmaceuticals Inc
    Regenesance BV
    Shire Plc
    Toleranzia AB
    UCB SA

    Request for Sample

    Report Url http://www.reportsweb.com//myasthenia-gravis-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//myasthenia-gravis-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//myasthenia-gravis-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments